Skip to main content
. 2024 Feb 22;25(5):2538. doi: 10.3390/ijms25052538

Figure 1.

Figure 1

Data aggregation workflow and overlap between test datasets. (A) Overlap between ChEMBL and KKB unique kinase inhibitors and targets. (B) ChEMBL and KKB small-molecule bioactivity data aggregation workflow.